These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38273183)

  • 1. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
    Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
    Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
    Siderova M; Hristozov K; Tsukeva A
    Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
    Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
    Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
    Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
    J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
    Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
    Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
    Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
    Park J; Kim J; Kim SS; Choi HY
    Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and natural history of Graves' orbitopathy in the XXI century.
    Piantanida E; Tanda ML; Lai A; Sassi L; Bartalena L
    J Endocrinol Invest; 2013 Jun; 36(6):444-9. PubMed ID: 23587873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.
    Kim JW; Han SH; Son BJ; Rim TH; Keum KC; Yoon JS
    Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):991-8. PubMed ID: 26876240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study.
    Le Moli R; Naselli A; Costanzo G; Piticchio T; Tumino D; Pellegriti G; Frasca F; Belfiore A
    Front Endocrinol (Lausanne); 2024; 15():1401155. PubMed ID: 39027472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Graves' orbitopathy].
    Balázs C
    Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
    Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
    Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.